ReviewDiscover oncology2026
The role of RARG in solid tumor progression and therapeutic potential.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Retinoic Acid Receptor γ Is a Ligand-Activated Gatekeeper to Stem Cell Developmental Progression.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Retinoic acid receptor gamma (RARG), a crucial member of the retinoic acid receptors (RARs) family, encompasses two distinct isoforms, namely RARγ1 and RARγ2. RARG is organized into five functional domains: A/B, C, D, E and F. Among them, the C region encodes the DNA-binding domain (DBD), which mediates recognition and binding to retinoic acid response elements (RAREs) in DNA, typically as a heterodimer with retinoid X receptors (RXRs). This RAR-RXR dimer mediates the genomic effects of RARG in a ligand-dependent manner. RARG can be directly activated by all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cisRA). In cancer cells with low endogenous levels of ATRA, RARG has been identified as a potential oncogenic driver. Recent research has increasingly implicated that RARG is involved in the initiation and progression of solid tumors through both genomic and non-genomic mechanisms. RARG regulates gene expression, cell proliferation and differentiation via Wnt/β-catenin, PI3K/AKT, Hippo-Yap, TRAF6-IL-6-STAT3 and other multiple signaling pathways. This review summarizes the structural and functional features of RARG, highlights its emerging roles in solid tumor biology and discusses therapeutic strategies targeting RARG, aiming to inform future cancer treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.